ArticleScientific reports2025
Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease.Advances in therapy · 2026Article
- Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.BMC pulmonary medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nintedanib is widely used to slow disease progression and prevent acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung disease (PF-ILD). We retrospectively analysed patients who initiated nintedanib for IPF or PF-ILD between August 2019 and July 2023 across 15 institutions in Japan, focusing on prognosis and disease progression. Patients were divided into two groups based on whether they survived for ≥ 3 years after nintedanib initiation, and their characteristics were compared. We also evaluated factors associated with annual forced vital capacity (FVC) decline and acute exacerbations. A total of 413 patients (171 with IPF and 242 with PF-ILD) were included. Median survival was 1,177 days for IPF and 1,268 days for PF-ILD, with no significant difference (P = 0.20). Patients surviving < 3 years were older (75.0 vs. 71.0 years), more frequently had resting arterial oxygen saturation (SpO2) < 95% (44.5% vs. 18.0%), and lower body mass index (BMI) (21.9 vs. 24.1 kg/m2). Additionally, patients with a BMI < 22 kg/m2 showed greater annual relative FVC decline. In conclusion, patients with IPF and PF-ILD showed comparable outcomes following nintedanib treatment. Age ≥ 65 years, resting SpO2 < 95%, and BMI < 22 kg/m2 were associated with shorter survival after nintedanib initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.